Integrin Ligand Mimetics Enhance Antibody Efficacy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a significant unmet need for safe and efficacious adjuvants that can potentiate the immune response in infectious, autoimmune, and allergic diseases, as well as in cancer, without unacceptable side effects or lack of biocompatibility.

Innovation Solution

The development of small molecule integrin ligand mimetics that facilitate integrin-ligand interactions, enhancing the priming of vaccines, cytolytic activity of adoptive cell therapies, immunotherapies, and biologic therapies by mechanisms including antibody-dependent cellular cytotoxicity (ADCC).

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional adjuvants (such as alum) are used to enhance immune response, then the immune response is boosted, but unacceptable side effects and lack of biocompatibility occur

Engineering Contradiction:

Improveimmune response enhancementVSAvoidside effects and toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of adjuvants by using small molecule integrin ligand mimetics with specific molecular structures (formulas I and II) that selectively activate integrins. This replaces conventional adjuvants like alum with molecules having controlled chemical properties that enhance immune response without the harmful side effects associated with traditional adjuvants.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces small molecule integrin ligand mimetics as intermediary substances that mediate between the vaccine antigen and the immune system. These mimetics facilitate integrin-ligand interactions to enhance immune response priming and effector functions, acting as a bridge that avoids the direct toxicity of conventional adjuvants while achieving the desired immunoenhancement.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If cytokines (such as GM-CSF) are used as adjuvants to enhance immune response, then specific immune features are enhanced, but the cost increases and stability decreases

Engineering Contradiction:

Improveimmune response enhancementVSAvoidstorage requirements and cost

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs small molecule integrin ligand mimetics that are chemically stable, cost-effective, and do not require the controlled storage conditions needed for cytokine-based adjuvants. These molecular mimetics serve as a stable, inexpensive alternative to biologic cytokines like GM-CSF, eliminating the need for cold chain storage and reducing overall cost while maintaining immune enhancement efficacy.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

3Object-affected harmful factors

If purified soluble recombinant antigens are used for vaccines, then tolerability improves, but immunogenicity decreases

Engineering Contradiction:

ImprovetolerabilityVSAvoidimmunogenicity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent uses small molecule integrin ligand mimetics as intermediary substances that bridge the gap between tolerability and immunogenicity. These mimetics enhance the immune response to purified soluble recombinant antigens by activating integrins that facilitate antigen presentation and immune cell interaction, thereby maintaining the tolerability advantages of subunit vaccines while restoring their immunogenicity through integrin-mediated priming and effector function enhancement.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These small molecule integrin ligand mimetics effectively enhance the therapeutic efficacy of vaccines, adoptive cell therapies, and immunotherapies for cancer and other conditions by improving immune response priming and effector functions.

Implementation Method 1

small molecule integrin ligand mimetics that facilitate integrin-ligand interactions

Methodology Applied

Scientific EffectIntegrin-ligand interactions: Adhesive

Implementation Method 2

mechanisms including antibody-dependent cellular cytotoxicity (ADCC)

Methodology Applied

Scientific EffectAntibody-dependent cellular cytotoxicity:

Data Source

PatentUS12201686B2Compositions including a therapeutic antibodies and/or a checkpoint inhibitor and an integrin activating compound

Publication Date: 2025.01.21 7 HILLS PHARMA LLC

AI summary

Pharmaceutical compositions including one or more integrin activating compounds capable of enhancing an anti-tumor activity of one or more therapeutic antibodies, one or more immune checkpoint inhibitors, or mixtures thereof.